Rebiotix

Roseville, United States Founded: 2011 • Age: 15 yrs Acquired By Ferring Pharmaceuticals
Microbiota restoration therapies are developed for gastrointestinal infections.
Request Access

About Rebiotix

Rebiotix is a company based in Roseville (United States) founded in 2011 was acquired by Ferring Pharmaceuticals in April 2018.. Rebiotix has raised $29.3 million across 3 funding rounds from investors including Ferring Pharmaceuticals. Rebiotix offers products and services including Donor Program. Rebiotix operates in a competitive market with competitors including Novozymes, Vir Biotechnology, Vaxcyte, Cidara Therapeutics and Freeline, among others.

  • Headquarter Roseville, United States
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Rebiotix Inc
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $29.3 M (USD)

    in 3 rounds

  • Latest Funding Round
    $8.52 M (USD), Series B

    Sep 05, 2017

  • Investors
  • Employee Count
    Employee Count
  • Acquired by
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Rebiotix

Rebiotix offers a comprehensive portfolio of products and services, including Donor Program. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Program for donor-related activities in pharmaceuticals context.

People of Rebiotix
Headcount 50-200
Employee Profiles 19
Employee Profiles
People
Karen Gott
Validation Engineer
People
Elad Fadlon
Information Technology System Analyst
People
Carol Bchara
Marketing Specialist
People
Lee Jones
Founder, President & CEO

Unlock access to complete

Funding Insights of Rebiotix

Rebiotix has successfully raised a total of $29.3M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $8.52 million completed in September 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Series B — $8.5M
  • First Round

    (04 Nov 2011)

  • Investors Count
Date Amount Transaction Name Valuation Lead Investors Investors
Sep, 2017 Amount Series B - Rebiotix Valuation

investors

Jul, 2014 Amount Series B - Rebiotix Valuation

investors

Nov, 2011 Amount Seed - Rebiotix Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Rebiotix

Rebiotix has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ferring Pharmaceuticals. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Provider of drugs in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Rebiotix

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Rebiotix

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Rebiotix Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Rebiotix

Rebiotix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Novozymes, Vir Biotechnology, Vaxcyte, Cidara Therapeutics and Freeline, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Biosolutions and enzymes are developed for biotechnology applications across industries.
domain founded_year HQ Location
Developer of therapeutics for the treatment of infectious diseases
domain founded_year HQ Location
Vaccines for infectious diseases are developed using cell-free protein synthesis.
domain founded_year HQ Location
Novel anti-infectives for bacterial and fungal infections are developed.
domain founded_year HQ Location
Gene therapy platform is developed for chronic disease treatments.
domain founded_year HQ Location
Prophylactic vaccines for infectious diseases are developed and advanced.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Rebiotix

When was Rebiotix founded?

Rebiotix was founded in 2011.

Where is Rebiotix located?

Rebiotix is headquartered in Roseville, United States. It is registered at Roseville, California, United States.

Is Rebiotix a funded company?

Rebiotix is a funded company, having raised a total of $29.3M across 3 funding rounds to date. The company's 1st funding round was a Seed of $2.78M, raised on Nov 04, 2011.

What does Rebiotix do?

Rebiotix was founded in 2011 and is headquartered in Roseville, United States. Biologic drugs are developed by the company for gastrointestinal diseases, with a focus on recurrent Clostridium difficile infections through microbiome-based approaches. RBX2660, a microbiota suspension derived from fecal transplants, is advanced as a primary therapy. Additional efforts target ulcerative colitis and metabolic syndrome within the biotechnology sector.

Who are the top competitors of Rebiotix?

Rebiotix's top competitors include Novozymes, Vaxcyte and Serum Institute of India.

What products or services does Rebiotix offer?

Rebiotix offers Donor Program.

Who are Rebiotix's investors?

Rebiotix has 1 investor. Key investors include Ferring Pharmaceuticals.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available